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Magalhães1,2, Jorge Augusto de Oliveira Guerra1,2, Henrique Silveira1,2,6, Max Jean de Ornelas Toledo4,
Maria das Graças Vale Barbosa1,2,7
1 Tropical Medicine Foundation Dr. Heitor Vieira Dourado, Manaus, Amazonas, Brazil, 2 University of the State of Amazonas, Manaus, Amazonas, Brazil, 3 Federal University
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Abstract
Background: In the Brazilian Amazon, clinical and epidemiological frameworks of Chagas disease are very dissimilar in
relation to the endemic classical areas of transmission, possibly due to genetic and biological characteristics of the
circulating Trypanosoma cruzi stocks. Twenty six T. cruzi stocks from Western Amazon Region attributed to the TcI and TcIV
DTUs were comparatively studied in Swiss mice to test the hypothesis that T. cruzi clonal structure has a major impact on its
biological and medical properties.
Methodology/Principal Findings: Seventeen parameters were assayed in mice infected with 14 T. cruzi strains belonging to
DTU TcI and 11 strains typed as TcIV. In comparison with TcI, TcIV stocks promoted a significantly shorter pre-patent period
(p,0.001), a longer patent period (p,0.001), higher values of mean daily parasitemia (p = 0.009) and maximum of
parasitemia (p = 0.015), earlier days of maximum parasitemia (p,0.001) and mortality (p = 0.018), higher mortality rates in
the acute phase (p = 0.047), higher infectivity rates (p = 0.002), higher positivity in the fresh blood examination (p,0.001),
higher positivity in the ELISA at the early chronic phase (p = 0.022), and a higher positivity in the ELISA at the late chronic
phase (p = 0.003). On the other hand TcI showed higher values of mortality rates in the early chronic phase (p = 0.014),
higher frequency of mice with inflammatory process in any organ (p = 0.005), higher frequency of mice with tissue
parasitism in any organ (p = 0.027) and a higher susceptibility to benznidazole (p = 0.002) than TcIV. Survival analysis
showing the time elapsed from the day of inoculation to the beginning of the patent period was significantly shorter for
TcIV strains and the death episodes triggered following the infection with TcI occurred significantly later in relation to TcIV.
The notable exceptions come from positivity in the hemocultures and PCR, for which the results were similar.
Conclusion/Significance: T. cruzi stocks belonging to TcI and TcIV DTUs from Brazilian Amazon are divergent in terms of
biological and medical properties in mice.
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Introduction
Chagas disease is an important health problem, affecting 8–9
million individuals, with approximately 50,000 new cases annu-
ally, in Central and Latin America [1]. The illness is caused by
Trypanosoma cruzi and has a variable clinical course that may
include symptomless infection, overwhelming acute disease or a
severe chronic condition. The latter may be hallmarked by
cardiovascular and/or gastrointestinal involvement. In the search
for improved sources of income, agriculture, livestock rearing, and
other socioeconomic activities, human populations began migrat-
ing into the natural wild habitats where T. cruzi infection was
enzootic [2]. Currently, poverty, poor housing and sub-standard
living conditions and deforestation promote an incipient adapta-
tion of triatomine vectors to both humans and domestic animals,
with increased efficiencies of the wild, domestic, and peridomestic
cycles of T. cruzi transmission in the areas where Chagas disease
emerges [2,3]. Furthermore, oral transmission through contami-
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nated food is now considered an important route of transmission
[4].
Trypanosoma cruzi is a heterogeneous taxon with multiple hosts,
vectors and routes of infection (for a review, see [5]). Multilocus
genotyping consistently reveals six ‘discrete typing units’ (DTUs)
[6], named as TcI to TcVI in the last T. cruzi nomenclature
consensus held in Brazil [7]. TcII, TcV and TcVI predominate in
the domestic transmission cycles in the South Cone of South
America, where patients may present severe acute disease with
chronic cardiac and/or digestive involvement [8]. In the Brazilian
Amazon, Venezuela, Colombia, Central and North America, TcI
is the predominant DTU and the major cause of both acute and
cardiac Chagas’ disease, but also is reported from chagasic patients
sporadically throughout the Southern Cone [9–12]. Unexpectedly,
TcI was reported beside TcII, TcIII, TcIV and TcV strains in
Mexico, at a relatively high frequency in Triatoma dimidiata [13].
TcIII is infrequent from domestic sources and circulates in
terrestrial transmission cycles associated with Dasypus novemcinctus
mainly throughout South America, causing at least three reported
cases of Chagas’ disease [14–16]. TcIV is found in Amazonia and
Southern North America, most frequently isolated from primates
and recently this DTU was associated to Chagas’ disease in the
Brazilian Amazon [17] and Venezuela [18].
To understand the diverse phenotypic differences among
different T. cruzi strains and the potential connection between
that variability and different manifestations of Chagas disease, it is
essential to have a correct reconstruction of the evolutionary
history of T. cruzi. There is solid evidence that T. cruzi genetic
structure is the outcome of recombination events detected as the
presence of naturally occurring hybrids [19], mitochondrial
introgression [17,19] and a capacity for genetic exchange in the
laboratory [20], occurring more commonly within epidemiolog-
ically linked strains [21]. Likewise, clonal diversity among humans,
reservoir hosts and vectors suggested complex patterns of
superinfection and/or coinfection in oral and vector-borne
Chagas’ disease cases [22]. Advances in the comprehension of
the molecular epidemiology of Chagas’ disease and geographic
distribution of the six DTUs were not accompanied by a similar
effort to straightforwardly elucidate the biological framework of
the stocks and clones studied both in the vertebrate hosts and
vectors. Some ancient studies have confirmed that T. cruzi genetic
diversity is correlated with the intrinsic characteristics of the
parasite such as the behavior in vitro [23,24], in the vector [25],
and in the vertebrate host, namely virulence [26], pathological
alterations and tropism toward specific organs [26,27].
In the Brazilian Amazon Region, Chagas’ disease has been
recognized as an important and emerging problem. The
epidemiological situation of Chagas’ disease in this region, where
enzootic T. cruzi transmission cycles involve a great diversity of
vectors and reservoir hosts [4,28], suitably illustrates the concerns
about the consolidation of Chagas’ disease control. Adventitious
adult triatomines maintain continuous, low-intensity transmission
in rural settings; as a result, human infection is hypo-endemic in
the region, with about 100,000 to 300,000 people chronically
carrying T. cruzi [4]. Sylvatic triatomines are also involved in
localized disease outbreaks related to oral T. cruzi transmission via
contaminated foodstuffs, and account for the relatively high
infection prevalence (4–5%) reported among extractivist forest
workers such as piaçava palm fiber collectors [4,28]. In this region
a few cases of chronic Chagas’ disease were reported, appearing
uniquely as miocardiopathy without records of digestive tract
pathology [29]. So far there is no information about the DTUs
responsible for chronic cases in the Brazilian Amazon. Isolates
from patients with acute Chagas’ disease were typed as TcI and Z3
(TcIII or TcIV) in the state of Pará [30] and as TcIV in two
outbreaks in the state of Amazonas [17].
The diverse clinical outcome of human T. cruzi infection has
been attributed to the genetic heterogeneity of parasite popula-
tions and to the host’s genetic background [31]. Miles et al. [9]
have suggested that the variability of clinical manifestations of the
disease could be in part explained by the parasite’s genetic
diversity. Knowledge on the parallel evolution between biological
differences and genetic divergence among T. cruzi natural stocks
is highly desirable because it may play an important role in
comparative researches on the clinico-epidemiological and
pathogenic perspectives. Predicting the clinical outcome of an
infection based on the infecting DTU (and to what extent it is
possible to do) is an important and worthy goal that needs
previous comparative biology studies. The aim of this work is to
carry out the biological characterization of T. cruzi isolates




The use of stocks of T. cruzi obtained from patients has been
approved by the Ethics in Research on Humans Committee of the
Tropical Medicine Foundation of the State of Amazonas (approval
number 360/07). Patients diagnosed with Chagas disease were
treated according to the guidelines of the Brazilian Health
Ministry. We obtained written informed consent from all
participants involved in our study. Marsupials’ captures and
handling for blood sample collection were performed according to
permits from the Brazilian Institute for Environment (approval
number 1830651/07). Use of mice in this study and all the
procedures using these animals were approved by the Ethics in
Research on Animal Committee of the State University of
Maringá (approval number 113/09). The procedures with the
animals followed the ethical principles for animal use in research
according to the Brazilian College of Animal Experimentation.
Author Summary
Chagas disease is caused by the protozoan parasite
Trypanosoma cruzi, constituting an important health
problem in the American Continent. In the Brazilian
Amazon, Chagas disease has been recognized as an
emerging problem. There are few studies exploring the
genetic and biological framework of stocks of T. cruzi from
the Western Brazilian Amazon, where Chagas disease has a
profile of lower morbidity and mortality, appearing mainly
in the chronic latent form. Here, we carried out the
biological characterization in mice of T. cruzi isolates
belonging to TcI and TcIV DTUs from the State of
Amazonas, Western Brazilian Amazon. T. cruzi stocks
belonging to TcI and TcIV DTUs from Brazilian Amazon
are divergent in terms of biological and medical properties
in mice, with a higher virulence for the latter DTU as
revealed by several biological parameters. Results strongly
support the working hypothesis that biological differences
are proportional to the evolutionary divergence among
the DTUs, and highlight the need to take into account the
phylogenetic diversity of T. cruzi natural stocks circulating
in the emergent areas for Chagas disease in all applied
studies dealing with clinical diversity of Chagas disease,
immunology, diagnosis, prognosis, and drug and vaccine
trials.
Comparative Biology of Trypanosoma cruzi I and IV
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Parasites stocks
All the stocks biologically characterized in this investigation
were isolated from municipalities distantly located in the State of
Amazonas (Fig. 1) and were genotyped previously as TcI or TcIV
[17]. Molecular characterization was performed by PCR of the
mini-exon [32] and ribosomal RNA [33] genes and by sequencing
of the mitochondrial cytochrome c oxidase subunit II [34] and
glucose-phosphate isomerase [20] genes. According to the T. cruzi
nomenclature consensus [7], we included a set of fourteen stocks
belonging to DTU TcI and a set of eleven stocks of the DTU
TcIV. Information on the laboratory code, host, method of
isolation, geographic origin, and DTU of these stocks is given in
Table S1. For more details about these procedures see Monteiro et
al. [17].
The methods used in this work were summarized in the Figure S1.
Inoculation of mice
For each T. cruzi stock, a group of 20 male Swiss mice aged 21–
28 days and weighting between 18 g and 20 g was used. All the
animals were supplied by the central bioterium of the State
University of Maringá and were kept under suitable temperature,
humidity, and availability of water and food ad libitum. Inoculation
was performed intraperitoneally and the inoculum was calculated
according to Brener [35], ranging from 2,86103 to 1.06104 blood
trypomastigotes per animal (Table S1). For experiments with
thirteen stocks presenting subpatent parasitemia in Swiss mice,
inoculum of metacyclic trypomastigotes from late-stationary-phase
culture in LIT medium [36] was employed. We used an inoculum
of 1,06106 metacyclic trypomastigotes per animal for histopath-
ological studies. The number of parasites was calculated by using a
Neubauer chamber, with the subsequent calculation of the
percentage of trypomastigotes in random counts of 500 forms on
a Giemsa-stained slide (Table S1).
Parasitological parameters
The curve of parasitemia was based on the search on
trypomastigotes forms in the bloodstream. Fresh blood examina-
tion (FBE) was daily carried out from the 3th day after inoculation
(d.a.i.) until the test became negative for at least three consecutive
days in the case of patent parasitemia or for a 30-day period in the
case of subpatent parasitemia. Counting of parasites was
performed on 5 mL of blood collected from the animal’s tail as
described by Brener [35]. In addition to determining the
percentage of animals presenting positive FBE (%+FBE), mean
pre-patent period (PPP), mean patent period (PP), mean daily
parasitemia (MDP), maximum peak of parasitemia (Pmax) and
day of maximum peak of parasitemia (DPmax) were obtained for
each DTU [26].
Hemoculture (HC)
On the 55th d.a.i., 0.5 mL of blood was aseptically collected
from the retro-orbital plexus and placed in two tubes containing
Figure 1. Geographic origin of the Trypanosoma cruzi strains from the State of Amazonas, Brazil.
doi:10.1371/journal.pntd.0002069.g001
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3 mL of LIT medium each, according to Filardi and Brener [37].
The cultures were kept at 28uC and monitored with microscopy
for parasite growth at 30, 45, and 60 days after seeding. This
technique allowed the percentage of mice presenting positive
hemoculture (%+HC) to be obtained for each DTU.
Polymerase Chain Reaction (PCR)
For PCR, blood samples were obtained at the same time that
HC was carried out. Two hundred microliters of blood from each
animal was added to double the volume of 6.0 M/0.2 M
guanidine/EDTA and stored at room temperature. The lysate
was boiled for 7 min and the DNA extraction carried out in an
aliquot of 100 mL using the Wincker et al. [38] protocol as
modified by Gomes et al. [39]. The DNA solution was then
washed with 70% ethanol prior to precipitation in order to remove
potential PCR inhibitors. Finally, the DNA was re-suspended in
10 mL H2O MiliQ. During this stage, one negative and one
positive control were added to each group of four samples. PCR
amplification was performed in a total volume of 11 mL, using 121
and 122 primers to amplify a specific fragment of 330 base pairs
(bp) of kinetoplast DNA (kDNA) of T. cruzi. The reaction mixture
was submitted to 35 amplification cycles with a thermocycler
(Techne TC-512, UK), using 95uC for 1 min for denaturation
with a longer initial time of 5 min, 65uC for 1 min for primer
annealing, and 72uC for 1 min for extension with a final
incubation at 72uC for 10 min. In this step, as a contamination
control, two negative and two positive controls from the extraction
step were added to every eight samples, and one negative and one
positive control to the PCR. All the stages were carried out in
separate environments with reagents, materials, and equipments
exclusive to each area. The PCR products were visualized in 4.5%
polyacrylamide silver-stained gel.
With the PCR results was obtained the parameter percentage of
mice with positive PCR (%+PCR) for each DTU [40].
Infectivity and mortality
The infectivity rate (%INF) was calculated as the percentage of
animals presenting positive FBE within the first two months
following inoculation and/or positive HC and/or PCR on the 55th
d.a.i. Cumulative mortality (%MOR) was recorded every day
during the infection course, being calculated as the percentage of
deaths observed in the acute (from inoculation until the 90th d.a.i)
and chronic phases (from the 90th until the 180th d.a.i.). Day of
maximum mortality (DMM) was determined by the mean of the
day when occurred the deaths for each DTU.
Enzyme-linked immunosorbent assay (ELISA)
An ELISA modified according to Voller et al. [41] was used.
Alkaline antigen of the T. cruzi Y (TcII) strain obtained in the
exponential growth phase in LIT medium, and peroxidase-labeled
anti-mouse immunoglobulin G conjugated (Bethyl Laboratories,
Montgomery, AL, USA) were used. Samples of serum collected in
the early chronic phase (115th d.a.i.) and in the late chronic phase
(205th d.a.i.) and diluted to 1:100 in phosphate-buffered saline,
were used. The mean absorbance for 10 negative-control serum
samples plus 2 standard deviations was used as the cut-off to
discriminate positive and negative results.
With the ELISA results was obtained the parameter percentage
of mice with positive ELISA (%+ELISA) for each DTU [40].
Susceptibility to benznidazole
After inoculation the animals were divided into two groups: 10
treated (T) and 10 untreated controls (NT). The first group was
treated orally with daily doses of benznidazole (Lafepe, Brazil)
100 mg/kg of body weight for 20 consecutive days, starting of the
5th day after inoculation [37]. From the 3rd d.a.i. mice were
subjected daily to FBE to confirm the infection and parasitemia
record before treatment starting. Benznidazole was suspended in
distilled water using Arabic gum and this suspension was
administered by gavage.
Both T and NT groups were submitted to different diagnostic
techniques for cure monitoring and determination of susceptibility
to BZ. Mice with negative FBE, HC, PCR and ELISA results after
completed treatment were considered cured [42]. Those with at
least one positive result in any test were considered non-cured.
The procedures for conducting these tests are the same as
described in previous items.
The cure rate in animals inoculated with each stock and treated
with benznidazole was obtained by the ratio between the number
of animals considered cured and the total treated animals 6100.
To determine the in vivo susceptibility of T. cruzi stocks to the
chemotherapeutic agent was adopted criterion similar to Toledo et
al. [42]: stocks with cure rates of 0% to 33% were resistant to the
drug, those with cure rates between 34% and 67% were
considered intermediate sensitivity and stocks with cure rates
above 67% were considered sensitive to the drug.
Histopathological parameters
Histopathological analysis was carried out on animals from
seven experiments with strains typed as TcI (AM28, AM38,
AM41, AM49 and AM61) and TcIV (AM69 and AM70) using
seven mice for each experiment. Infection was confirmed by FBE
and/or HC. For each T. cruzi stock, all infected surviving mice
were necropsied on the 90th d.a.i. for histopathological studies.
The following organs and tissues were collected: (1) heart, (2)
skeletal muscle, (3) lungs, (4) large intestine, (5) brain, (6) liver and
(7) spleen. This material was routinely processed and embedded in
paraffin. Five-micrometer sections of three blocks containing every
organ of each mouse were obtained for further evaluation. These
preparations were stained with hematoxylin-eosin for microscopic
examination. The tissue parasitism (TP) and inflammatory process
(IP) displayed by different organs or tissues were classified as
absent, mild, moderate or severe. With these results was obtained
the frequency of mice with inflammatory process and tissue
parasitism for each DTU.
Statistical analysis
Data were analyzed using SPSS version 16.0 for Windows
(SPSS Inc., Chicago, IL, USA). Normal distribution of data was
evaluated with the Kolmogorov-Smirnov test. Chi-square or
Fisher’s test was used to test differences in proportions, and
Student t test was used to test differences in means. Levene’s test
was used to assess the equality of variances in different samples
(DTUs). A Kaplan-Meier survival analysis was performed in order
to detect differences in the time elapsed from the day of
inoculation to the death episodes and the beginning of the patent
period between mice inoculated with TcI and TcIV DTUs of T.
cruzi. Log-rank test was used to test differences. Statistical
significance was considered if p,0.05.
Results
Significant mean and frequency differences are apparent for
biological properties in Swiss mice between the TcI and TcIV
stocks. The statistical comparison evidenced that 15 out 17
parameters demonstrated significant differences between the
DTUs (Tables 1 and 2). TcIV stocks promoted a significantly
Comparative Biology of Trypanosoma cruzi I and IV
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shorter PPP (p,0.001), a longer PP (p,0.001), higher values of
MDP (p = 0.009) and Pmax (p = 0.015), and an earlier DMP
(p,0.001) and DMM (p = 0.018), in comparison with TcI. A great
standard deviation was observed in these biological parameters,
mainly in PP, MDP, Pmax, and DMM showing that stocks of the
same genetic lineage were not homogeneous in their character-
istics (Table 1). Figure 2 shows how dissimilar are the curves of
mean parasitemia built for TcI and TcIV strains and highlights the
higher and earlier parasitemia observed for TcIV. Area under the
curve was significantly greater for the set of TcIV strains
(p,0.001).
In the Table 2 are seen that TcIV stocks showed higher values
of %MOR in the acute phase (p = 0.047), %INF (p = 0.002),
%+FBE (p,0.001), %+ELISA in the early chronic phase
(p = 0.022), and %+ELISA in the late chronic phase (p = 0.003)
than the TcI strains. On the other hand TcI showed higher values
of %MOR in the chronic phase (p = 0.014), frequency of mice
with inflammatory process in any organ (p = 0.005), frequency of
mice with tissue parasitism in any organ (p = 0.027) and
susceptibility to benznidazole (p = 0.002) than TcIV. The notable
exceptions come from parameters obtained through amplification
methods of diagnosis (%+HC and %+PCR), for which no result is
statistically significant (p,0.05) (Table 2). Stocks presenting
resistance to benznidazole were found uniquely within TcIV
stocks (3/10). Tissue parasitism and severe or moderate inflam-
matory process in the early chronic phase were recorded only in
mice inoculated with TcI strains (Table 3). Amastigote nests were
observed only in heart tissue and inflammatory process was
observed in heart, skeletal muscle and brain.
Kaplan-Meier survival analysis showing the time elapsed from
the day of inoculation to the beginning of the patent period was
significantly shorter for TcIV strains and the death episodes
triggered following the infection with TcI occurred significantly
later in relation to TcIV (Figure 3).
Discussion
Several studies of the properties of T. cruzi in cell and acellular
cultures [23,24,43], virulence and pathogenicity in mice
[23,26,44,45], development in vectors [25,46] and response to
specific chemotherapy [24,42,47,48] support a strong association
between genetic distance and the biological and medical properties
of the parasite. The above-mentioned studies have brought
significant contributions, but none of them relied on a population
genetic framework representative of the emergent Chagas disease
areas, represented in Brazil by the Amazon region. Furthermore,
to our knowledge, this is the first investigation focusing on
biological and medical properties of TcIV strains from Amazon
Table 1. Mean values of biological parameters from
Trypanosoma cruzi I and IV strains.
Discrete typing unit (DTU)




Mean patent period (in days) 0.260.6 4.662.9 ,0.001




Day of maximum parasitemia 1560.8 7.460.5 ,0.001




aNumber of trypomastigotes/0,1 mL of blood.
bp,0.05: significant difference in the T-student test.
doi:10.1371/journal.pntd.0002069.t001
Table 2. Virulence parameters obtained in Swiss mice from Trypanosoma cruzi I and IV strains.
Discrete typing unit (DTU)
Parameter TcI TcIV p(f)
Mortality rate in the acute phase (%)(a) 2.4 12.3 0.047
Mortality rate in the chronic phase (%)(b) 9.8 1.2 0.014
Infectivity rate (%)(c) 64.9 84.4 0.002
Mice with positive fresh blood examination (%) 7.9 79.5 ,0.001
Mice with positive hemoculture (%) 64.7 49.4 0.061
Mice with positive PCR (%) 60.9 45.6 0.109
Mice with inflammatory process in any organ (%) 81.3 28.6 0.005
Mice with parasitism in any organ (%) 12.5 0.0 0.027
Susceptibility to benznidazole (%) 80.6 57.0 0.002
%+ELISA in the early chronic phase(d) 53.8 82.8 0.022
%+ELISA in the late chronic phase(e) 20.0 87.5 0.003
Number of significant differences 9/11
aCumulative mortality from inoculation until the 90th day after inoculation (d.a.i);
bCumulative mortality from the 90th until the 180th d.a.i.;
cPercentage of animals presenting positive fresh blood examination within the first two months following inoculation and/or positive hemoculture and/or PCR on the
55th d.a.i.;
dPercentage of animals presenting positive ELISA in the 115th d.a.i.;
ePercentage of animals presenting positive ELISA in the 205th d.a.i..
fp,0.05: significant difference; N.S.: not significant.
doi:10.1371/journal.pntd.0002069.t002
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Region. Human acute Chagas disease caused by this DTU has
been described [15] and recently, our group reported that the
majority of the acute cases in the Western Brazilian Amazon,
including outbreaks by oral transmission, were triggered by TcIV
[17].
In this work TcIV showed clearly higher virulence in comparison
with TcI strains, as demonstrated by the higher values of parasitemia
parameters and shortest PPP. TcI strains promoted predominantly
subpatent and intermittent parasitemias, in agree with the results
obtained from previous experimental studies using TcI from the
Amazon region [49]. Furthermore, TcIV parasites were more infective
for mice and promoted higher mortality in the acute phase, while TcI
led to higher mortality in the chronic phase. However, taking into
account the mortality parameter, we suggest that both DTUs had low
virulence, since a previous report demonstrated that T. cruzi stocks
(both TcI and TcII) isolated from patients in the acute phase killed
100% of the animals [50].
Previous reports have shown a great competence of TcII strains to
invade human and monkey cells [51,52], to infect and render patent
parasitemias in mice [53] and to infect and multiplicate inside
macrophages [54] in comparison to TcI strains. However, it has to be
mentioned that some discrepant results were reported as well. Revollo
et al. [24], for instance, showed that TcI parasites displayed a higher
infection rate to Vero cell monolayers than TcII stocks. Some works
demonstrated that TcI strains have a greater ability to complete its life
cycle in the vector [25,46], and a higher capacity for intracellular
multiplication in the vertebrate host populations, leading to higher
parasitemias in comparison to TcII [26,45,55,56]. In a study
conducted with TcI and TcIV isolates from United States, the two
T. cruzi DTUs caused differential infection dynamics in mice and rats
as determined by PCR detection of T. cruzi DNA in the blood and
tissues [57]. These authors found that sylvatic TcI isolates from the
United States had greater infectivity to laboratory rodents than TcIV
isolates, contradicting our results with isolates from Brazilian Amazon.
Despite being indistinguishable by traditional genotyping and generally
being assigned to Z3, there are evidences that TcIV from South
America and TcIV from North America correspond to independent
lineages using cytochrome b and SSU rDNA sequences, which
circulate in distinct hosts and ecological niches [58].
The histopathological results revealed in general the presence of
few amastigotes nests and mild inflammatory lesions. TcI triggered
inflammatory process in skeletal muscle, heart and brain, while
TcIV promoted mild inflammatory process uniquely in skeletal
muscle. Parasitism was observed only in 4 mice examined, all
infected by two TcI strains (AM49 and AM61), that presented
well-limited pseudocysts surrounded by mild inflammatory reac-
tion. Moreover, severe inflammatory process occurred only in
skeletal muscle of mice infected by TcI. Histopathological
alterations were not observed in large intestine, liver and, spleen
of infected mice. Thus, although the lower values of parasitemia,
TcI determined relatively most severe inflammatory process and
higher frequency of tissue parasitism in mice than TcIV.
Although TcIV stocks have been demonstrated higher virulence
than TcI, its pathogenicity was also incipient. These data taken
together emphasize that the biological and medical properties of
the stocks from this area are crucial to be considered in researches
about the clinical end epidemiological picture of Chagas disease in
the Amazon context. These profiles agree with the hypothesis of
authors who suggested that the framework of chronic latent
infection and a relative low performance of diagnostic tests in the
State of Amazonas are due to the lower parasitemia, virulence,
and pathogenicity of the wild parasites in this area [29]. However,
pathogenicity triggered by TcIV should be interpreted with
caution, since there were documented cases of chronic Chagas
heart disease caused by TcI/TcIV mixed infections in Colombia
[59], and two cases of chronic disease with cardiac/digestive
involvement associated with Z3 parasite that clustered with
CANIII (prototype of the TcIV DTU) at the isoenzymic analysis
in Ecuador [60]. In the Western Brazilian Amazon, TcIV has
been associated with two outbreaks of acute Chagas disease
probably linked to oral transmission [17].
Table 3. Number of mice infected with Trypanosoma cruzi I
and IV strains presenting histopathological alterations.
Parameter Intensity DTU
TcI (n = 32) TcIV (n = 7)
Tissue parasitism Mild 4 0
Absent 28 7





Figure 2. Curves of mean parasitemia obtained from Trypanosoma cruzi I and IV strains.
doi:10.1371/journal.pntd.0002069.g002
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Resistance to benznidazole was significantly higher for TcIV
strains. In vitro [24,61] and in vivo [42,47,48] studies found that
clones belonging to the lineage TcI are more resistant to
benznidazole and nifurtimox than that belonging to the lineage
TcII. Actually, as observed in central Brazil, patients infected with
TcI strains showed higher resistance to chemotherapy with
benznidazole compared with those infected with TcII [62]. Murta
et al. [63] reported higher efficiency of chemotherapy with
benznidazole and nifurtimox in human disease in areas with high
prevalence of hybrid zymodemes. However, preliminary data
about the response to specific chemotherapy in patients from
outbreaks related to oral transmission in areas of predominance of
TcI in the Amazon Region have been shown high parasitological
cure rates and decrease of the antibody titres [30,64], reinforcing
that TcI isolates from Brazilian Amazon poses a dissimilar
behavior when compared to other areas.
The seminal biological studies have demonstrated the huge
heterogeneity of T. cruzi parasites, but were probably hampered by
the fact that recent and unexpanded isolates from wild environ-
ment were not frequently used. Our work includes non- or low-
passaged parasite natural stocks and contributes to diminish this
biased sampling. A limitation of this approach may be the
instability of the composition of these stocks, but we believe that
our methodology better simulates what happens in nature, where
populations are often identified in multiclonality in vertebrate
hosts and triatomines [5]. Results strongly support the working
hypothesis that biological differences are proportional to the
evolutionary divergence among the DTUs. This shows that
evolutionary divergence and biological differences do not evolve
independently, and can be statistically predicted from each other
to a large extent. We highlight the need to take into account the
phylogenetic diversity of T. cruzi natural stocks circulating in the
emergent areas for Chagas disease in all applied studies dealing
with clinical diversity of Chagas disease, immunology, diagnosis,
prognosis, and drug and vaccine trials. The potential of the two
lineages in terms of severity and clinical manifestations remains to
be determined in humans, namely for TcIV strains.
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